[Form 4] Supernus Pharmaceuticals, Inc. Insider Trading Activity
Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals (SUPN), reported equity transactions dated 08/25/2025. The report shows the settlement of 1,250 shares upon vesting of Performance Share Units awarded on February 23, 2023, and 581 shares were withheld by the company to satisfy tax withholding at an indicated price of $41.46 per share. Following these transactions, the reporting person beneficially owned 13,718 shares of common stock. The filing explains the PSUs vested after achievement of individual performance objectives established June 12, 2023. The form was signed by an attorney-in-fact on behalf of the reporting person on 08/27/2025.
Padmanabh P. Bhatt, Senior Vice President of IP e Chief Scientific Officer di Supernus Pharmaceuticals (SUPN), ha segnalato operazioni su titoli in data 25/08/2025. La comunicazione riporta la liquidazione di 1.250 azioni a seguito del consolidamento di Performance Share Units assegnate il 23 febbraio 2023, e che 581 azioni sono state trattenute dall鈥檃zienda per soddisfare le ritenute fiscali, al prezzo indicato di $41,46 per azione. Dopo queste operazioni, la persona segnalante risultava titolare beneficiaria di 13.718 azioni ordinarie. Il modulo specifica che le PSU sono maturate dopo il raggiungimento degli obiettivi di performance individuali stabiliti il 12 giugno 2023. Il documento 猫 stato firmato da un procuratore in data 27/08/2025.
Padmanabh P. Bhatt, Senior Vice President of IP y Chief Scientific Officer en Supernus Pharmaceuticals (SUPN), inform贸 transacciones de valores con fecha 25/08/2025. El informe muestra la liquidaci贸n de 1.250 acciones tras el devengo de Performance Share Units otorgadas el 23 de febrero de 2023, y que la empresa retuvo 581 acciones para cubrir las retenciones fiscales, al precio indicado de $41.46 por acci贸n. Tras estas operaciones, la persona informante pose铆a beneficiariamente 13.718 acciones de acciones ordinarias. El formulario explica que las PSU vencieron tras el logro de objetivos individuales de desempe帽o establecidos el 12 de junio de 2023. El documento fue firmado por un apoderado el 27/08/2025.
Padmanabh P. Bhatt, Supernus Pharmaceuticals(SUPN) IP 靾橃劃 攵�靷灔鞚挫瀽 斓滉碃 瓿柬暀 毂呾瀯鞛愲姅 2025-08-25鞛� 歃濌秾 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 氤搓碃靹滌棎電� 2023雲� 2鞗� 23鞚检棎 攵�鞐悳 靹标臣欤�(Performance Share Units)鞚� 頇曥爼鞙茧 1,250欤缄皜 鞝曥偘霅橃棃瓿�, 靹戈笀 鞗愳矞歆曥垬毳� 鞙勴暣 須岇偓臧� 581欤茧ゼ 氤措頄堨溂氅� 欤茧嫻 響滌嫓 臧�瓴╈潃 $41.46鞚措澕瓿� 雮橃檧 鞛堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 氤搓碃 雽�靸侅瀽電� 氤错喌欤� 13,718欤�毳� 鞁れ 氤挫湢頃� 瓴冹溂搿� 雮橅儉雮姷雼堧嫟. 靹滊鞐愲姅 PSU臧� 2023雲� 6鞗� 12鞚检棎 靹れ爼霅� 臧滌澑 靹标臣 氇╉憸 雼劚 頉勳棎 頇曥爼霅橃棃雼り碃 靹る獏霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞏戩嫕鞚� 2025-08-27鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Padmanabh P. Bhatt, Senior Vice President of IP et Chief Scientific Officer chez Supernus Pharmaceuticals (SUPN), a d茅clar茅 des op茅rations sur titres dat茅es du 25/08/2025. Le rapport indique la r茅gularisation de 1 250 actions suite au vesting de Performance Share Units attribu茅es le 23 f茅vrier 2023, et que la soci茅t茅 a retenu 581 actions pour couvrir les pr茅l猫vements fiscaux, au prix indiqu茅 de 41,46 $ par action. Apr猫s ces op茅rations, la personne d茅clarante d茅tenait b茅n茅ficiairement 13 718 actions ordinaires. Le formulaire pr茅cise que les PSU sont vest茅es apr猫s l鈥檃tteinte des objectifs de performance individuels 茅tablis le 12 juin 2023. Le document a 茅t茅 sign茅 par un mandataire le 27/08/2025.
Padmanabh P. Bhatt, Senior Vice President of IP und Chief Scientific Officer bei Supernus Pharmaceuticals (SUPN), meldete Wertpapiergesch盲fte vom 25.08.2025. Der Bericht weist die Abwicklung von 1.250 Aktien infolge der Vesting von Performance Share Units auf, die am 23. Februar 2023 gew盲hrt wurden, und dass das Unternehmen 581 Aktien einbehalten hat, um die Steuerabz眉ge zu erf眉llen; der angegebene Preis betrug $41,46 je Aktie. Nach diesen Transaktionen besa脽 die meldende Person wirtschaftlich 13.718 Stammaktien. Das Formular erkl盲rt, dass die PSUs nach Erreichen der am 12. Juni 2023 festgelegten individuellen Zielvorgaben vesteten. Das Formular wurde am 27.08.2025 von einem Bevollm盲chtigten unterschrieben.
- Performance-based vesting occurred: 1,250 PSUs settled, indicating performance objectives were met as described in the filing.
- Administrative tax withholding was handled via withholding of 581 shares, demonstrating routine compliance with tax obligations on equity awards.
- Net beneficial ownership decreased to 13,718 shares after withholding, representing fewer shares retained by the reporting person.
Insights
TL;DR: Routine executive equity settlement and tax withholding; shows performance-based compensation vesting without material change to control.
This Form 4 records a standard settlement of Performance Share Units (1,250 shares) and subsequent tax-withholding disposition (581 shares). The disclosure confirms the award was performance-based with objectives set June 12, 2023, and settled August 25, 2025. The net beneficial ownership reported (13,718 shares) is a factual update rather than a change in governance or control. There is no indication of option exercises, pledges, or transfers to related parties in the filing.
TL;DR: Indicates PSU vesting and routine tax-withholding; reflects compensation realization for the executive.
The transaction codes show Code M for settlement of PSUs and Code F for shares withheld to satisfy taxes at $41.46 per share. The filing identifies the original grant date (02/23/2023) and that vesting was tied to individual performance objectives. This is a standard post-vesting administrative outcome that converts long-term incentive units into common stock while covering withholding obligations, reducing share count delivered to the executive by 581 shares.
Padmanabh P. Bhatt, Senior Vice President of IP e Chief Scientific Officer di Supernus Pharmaceuticals (SUPN), ha segnalato operazioni su titoli in data 25/08/2025. La comunicazione riporta la liquidazione di 1.250 azioni a seguito del consolidamento di Performance Share Units assegnate il 23 febbraio 2023, e che 581 azioni sono state trattenute dall鈥檃zienda per soddisfare le ritenute fiscali, al prezzo indicato di $41,46 per azione. Dopo queste operazioni, la persona segnalante risultava titolare beneficiaria di 13.718 azioni ordinarie. Il modulo specifica che le PSU sono maturate dopo il raggiungimento degli obiettivi di performance individuali stabiliti il 12 giugno 2023. Il documento 猫 stato firmato da un procuratore in data 27/08/2025.
Padmanabh P. Bhatt, Senior Vice President of IP y Chief Scientific Officer en Supernus Pharmaceuticals (SUPN), inform贸 transacciones de valores con fecha 25/08/2025. El informe muestra la liquidaci贸n de 1.250 acciones tras el devengo de Performance Share Units otorgadas el 23 de febrero de 2023, y que la empresa retuvo 581 acciones para cubrir las retenciones fiscales, al precio indicado de $41.46 por acci贸n. Tras estas operaciones, la persona informante pose铆a beneficiariamente 13.718 acciones de acciones ordinarias. El formulario explica que las PSU vencieron tras el logro de objetivos individuales de desempe帽o establecidos el 12 de junio de 2023. El documento fue firmado por un apoderado el 27/08/2025.
Padmanabh P. Bhatt, Supernus Pharmaceuticals(SUPN) IP 靾橃劃 攵�靷灔鞚挫瀽 斓滉碃 瓿柬暀 毂呾瀯鞛愲姅 2025-08-25鞛� 歃濌秾 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 氤搓碃靹滌棎電� 2023雲� 2鞗� 23鞚检棎 攵�鞐悳 靹标臣欤�(Performance Share Units)鞚� 頇曥爼鞙茧 1,250欤缄皜 鞝曥偘霅橃棃瓿�, 靹戈笀 鞗愳矞歆曥垬毳� 鞙勴暣 須岇偓臧� 581欤茧ゼ 氤措頄堨溂氅� 欤茧嫻 響滌嫓 臧�瓴╈潃 $41.46鞚措澕瓿� 雮橃檧 鞛堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 氤搓碃 雽�靸侅瀽電� 氤错喌欤� 13,718欤�毳� 鞁れ 氤挫湢頃� 瓴冹溂搿� 雮橅儉雮姷雼堧嫟. 靹滊鞐愲姅 PSU臧� 2023雲� 6鞗� 12鞚检棎 靹れ爼霅� 臧滌澑 靹标臣 氇╉憸 雼劚 頉勳棎 頇曥爼霅橃棃雼り碃 靹る獏霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞏戩嫕鞚� 2025-08-27鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Padmanabh P. Bhatt, Senior Vice President of IP et Chief Scientific Officer chez Supernus Pharmaceuticals (SUPN), a d茅clar茅 des op茅rations sur titres dat茅es du 25/08/2025. Le rapport indique la r茅gularisation de 1 250 actions suite au vesting de Performance Share Units attribu茅es le 23 f茅vrier 2023, et que la soci茅t茅 a retenu 581 actions pour couvrir les pr茅l猫vements fiscaux, au prix indiqu茅 de 41,46 $ par action. Apr猫s ces op茅rations, la personne d茅clarante d茅tenait b茅n茅ficiairement 13 718 actions ordinaires. Le formulaire pr茅cise que les PSU sont vest茅es apr猫s l鈥檃tteinte des objectifs de performance individuels 茅tablis le 12 juin 2023. Le document a 茅t茅 sign茅 par un mandataire le 27/08/2025.
Padmanabh P. Bhatt, Senior Vice President of IP und Chief Scientific Officer bei Supernus Pharmaceuticals (SUPN), meldete Wertpapiergesch盲fte vom 25.08.2025. Der Bericht weist die Abwicklung von 1.250 Aktien infolge der Vesting von Performance Share Units auf, die am 23. Februar 2023 gew盲hrt wurden, und dass das Unternehmen 581 Aktien einbehalten hat, um die Steuerabz眉ge zu erf眉llen; der angegebene Preis betrug $41,46 je Aktie. Nach diesen Transaktionen besa脽 die meldende Person wirtschaftlich 13.718 Stammaktien. Das Formular erkl盲rt, dass die PSUs nach Erreichen der am 12. Juni 2023 festgelegten individuellen Zielvorgaben vesteten. Das Formular wurde am 27.08.2025 von einem Bevollm盲chtigten unterschrieben.
FAQ
What did SUPN insider Padmanabh Bhatt report on Form 4?
When were the Performance Share Units originally granted?
What was the tax withholding amount per share reported?
What is the reporting person's role at SUPN?
Who signed the Form 4 and when?
